Clinical trials: Schizophrenia Prodromal
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Prodromal Schizophrenia
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis.
- Trial name
- NCT03970005
- Testing
- Step-Based Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Prodromal Schizophrenia
Neurofeedback Training for High Risk Psychosis
Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community.
- Trial name
- NCT03447548
- Testing
- Neurofeedback processing speed training, Active control
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Hartford Hospital
At Risk Mental State (ARMS), Psychosis
Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS.
- Trial name
- NAYAB (NCT02569307)
- Testing
- Minocycline, Omega-3 fatty acids, Minocycline Plus Omega-3 fatty acids
- Where
- 7 sites in Pakistan
- Volunteers
- 326 people
- Sponsor
- Pakistan Institute of Living and Learning
Psychotic Disorders, Prodromal Symptoms
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
The present study is a confirmatory efficacy trial of Family Focused Therapy for youth at clinical high risk for psychosis (FFT-CHR).
- Conditions
- Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis
- Trial name
- NCT04338152
- Testing
- Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
- Where
- 7 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Prodromal Schizophrenia, Psychotic Disorders
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to…
- Trial name
- NCT00169988
- Testing
- risperidone, sertraline-primary
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder)
Online Intervention To Improve Motivation
Participants will complete one online intervention lasting 12 weeks. Each week, they will be asked to complete a 20-30 minute session online.
- Conditions
- Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder), Psychosis
- Trial name
- Online Mot (NCT07157293)
- Testing
- Online Motivation Enhancing Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia Prodromal, Schizophrenia, Childhood
Patientheque in Patients With a Psychosis
Establishment of a patient library for patients who have had a first psychotic episode and who have an "at risk" status for psychotic disorder (GRD, APS, BLIPS group) or a psychosis threshold during CAARMS administration.
- Conditions
- Schizophrenia Prodromal, Schizophrenia, Childhood, Schizophrenia
- Trial name
- LONGIPEP (NCT05340348)
- Testing
- Blood samples (36 mL) + fecal samples + hair sample
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Brest
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Glycine Treatment of Prodromal Symptoms
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.
- Trial name
- NCT00268749
- Testing
- glycine
- Volunteers
- 10 people
- Sponsor
- Yale University
Prodromal Schizophrenia
Early Detection and Intervention for Women At-risk of Psychosis
This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.
- Trial name
- NCT03751865
- Testing
- CBT, Psychoeducation
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Psychotic Disorders, Psychiatric Hospitalization
Youth Experiences and Health Study
This study aims to identify unusual experiences and psychiatric symptoms that indicate a heightened risk for severe mental disorders - especially psychoses.
- Conditions
- Psychotic Disorders, Psychiatric Hospitalization, Prodromal Symptoms, Cannabis Use
- Trial name
- YEAH (NCT03332966)
- Testing
- Psychiatric questionnaires, Semi-structured psychiatric interview
- Where
- 3 sites in Finland
- Volunteers
- 1,000 people
- Sponsor
- Finnish Institute for Health and Welfare
Prodromal Schizophrenia, Psychotic Episode
REtinal and VIsual Cortical Response in Early PSYchosis
The purpose of the REVIPSY study is to measure retinal and the visual cortical electrophysiological responses in situations at risk of psychosis in patients who have experienced a first psychotic episode.
- Conditions
- Prodromal Schizophrenia, Psychotic Episode, Prodromal Symptoms, Healthy Controls
- Trial name
- REVIPSY (NCT05167396)
- Testing
- Retinaute (BioSerenity), EEG Headset 64 electrodes (BioSemi), MonPackOne (Metrovision)
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Centre Psychothérapique de Nancy
Schizophrenia, Psychoses
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used.
- Trial name
- NCT00204061
- Testing
- Supportive management, Amisulpride
- Where
- Germany
- Volunteers
- 124 people
- Sponsor
- University of Cologne
Schizophrenia, Psychosis
Multi-site Communication Deficits in Schizophrenia
Multi-site Communication Deficits Underlying Cognitive Dysfunction in the Prodromal Phase and First Episode of Schizophrenia
- Trial name
- NCT01317121
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Prodromal Schizophrenia
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning.
- Trial name
- ESPRIT-B1 (NCT03149107)
- Testing
- N-Acetylcysteine, IPPI (Integrated Preventive Psychological Intervention), PSM (Psychological stress management)
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bonn
Prodromal Schizophrenia
Effects of NAC on Symptoms of CHR Patients
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals…
- Trial name
- NCT05142735
- Testing
- N-Acetylcysteine
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Centre for Addiction and Mental Health
Early Psychosis, Schizophrenia Prodromal
Perception and Integration of Sensory Information in the Early Stages of Psychosis
The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls.
- Trial name
- PRIOR-ePSY (NCT07446569)
- Testing
- behavioral tasks, Electroretinography, Comprehensive Assessment of At Risk Mental States (CAARMS)
- Where
- 4 sites in France
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Centre Psychothérapique de Nancy